# Vincent Lepreux

> Vincent Lepreux is a seed investor at Debiopharm Innovation Fund backing Software and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Debiopharm Innovation Fund](https://shizune.co/investors/profile/debiopharm-innovation-fund)
- Total investments: 5
- Last investment: Mar 2025
- Lead investor: 80%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/vlepreux

Vincent Lepreux is an Investment Director at Debiopharm Innovation Fund

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 2 | 40% |
| Health Care | 2 | 40% |
| Pharmaceutical | 2 | 40% |
| B2B | 1 | 20% |
| PaaS | 1 | 20% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 40% |
| Series A | 1 | 20% |
| Funding Round | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 40% |
| Israel | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MedaSystems | A cloud platform empowering global expanded and managed access programs. |  | Seed | Mar 05, 2025 |  |
| Strategikon Pharma | Clinical Maestro™ by Strategikon Pharma is the only commercially available software platform for the end- to- end management of “clinical business operations”, which is the pharmaceutical industry vertical for planning, outsourcing and budgeting clinical trials. Biopharmaceutical companies outsource 90% of their clinical development pipelinespending billions of dollars engaging in highly complex outsourced relationships with thousands of global service providers, each using their own processes, systems and reporting structures. These sophisticated relationships require complex outsourcing strategies, demanding clinical financial planning, extensive sourcing due diligence and rigorous performance management. Currently the industry manages these activities in Excel, using labor intensive, inefficient processes, costing billions of dollars in infrastructure costs, regulatory non-compliance fines and delays to market. Clinical Maestro takes a radically different approach to the management of clinical portfolio through a transformative redesign of Excel-driven processes into end-to-end integrated workflows, breaking the communication and data integration siloes between pharma companies and their outsourcing partners. Clinical Maestro™ cases studies with leading pharmaceutical companies and CROs demonstrate savings of >80% vs. manual processes, >95% prediction accuracy for clinical study budgets and high user satisfaction and engagement. | $7M | Series A | Feb 06, 2024 |  |
| MedaSystems | A cloud platform empowering global expanded and managed access programs. |  |  | Jan 09, 2024 |  |
| MedaSystems | A cloud platform empowering global expanded and managed access programs. |  | Seed | Jan 09, 2024 |  |
| Yonalink | YonaLink is a global network of over 30,000 medical centers that provides EHR-to-EDC streaming and AI-driven CRF data mapping. YonaLink collects clinical trial data in real-time, improves trial efficiency and data quality, reduces medical center staff burnout, and provides wider access to novel patient care opportunities. | $6M | Seed | Nov 08, 2022 |  |

5 of 5 investments shown.

## Co-investors
- [eHealth Ventures](https://shizune.co/investors/profile/ehealth-ventures) — VC Fund, 1 deal together
- [European Union](https://shizune.co/investors/profile/european-union) — VC Fund, 1 deal together
- [Golden Seeds](https://shizune.co/investors/profile/golden-seeds) — VC Fund, 1 deal together
- [HearstLab](https://shizune.co/investors/profile/hearstlab-36b3) — VC Fund, 1 deal together
- [Nina Capital](https://shizune.co/investors/profile/nina-capital) — VC Fund, 1 deal together
- [Osage Venture Partners](https://shizune.co/investors/profile/osage-partners) — VC Fund, 1 deal together

## About Debiopharm Innovation Fund

VC Fund · Lausanne, Switzerland

Debiopharm Innovation Fund invests in digital health companies that have an impact on cancer, infectious diseases, and drug development. We are looking for ambitious entrepreneurs raising series A or B with clinically proven, transformative technologies that use AI and data to help patients. We do not invest in consumer wellness or workflowsolutions. Our initial investment is typically $2-5M. Along with capital we bring deep pharma knowledge & networks and long-term commitment to help build value in your company. We are an evergreen investment fund of the pharmaceutical company Debiopharm based in Lausanne, Switzerland.

5 contacts available at Debiopharm Innovation Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Cedric Odje | Senior Investment Associate | https://shizune.co/investors/profile/cedric-odje |
| Nicole Wilson | Senior Administrative Assistant | https://shizune.co/investors/profile/nicole-wilson-10b6 |
| Tanja Dowe | Chief Executive Officer | https://shizune.co/investors/profile/tanja-dowe |
| Thomas Gibbs | Director | https://shizune.co/investors/profile/tom-gibbs |
| Vincent Lepreux | Investment Principal | https://shizune.co/investors/profile/vincent-lepreux |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Vincent Lepreux invest in?

Vincent Lepreux invests primarily in Software, Health Care and Pharmaceutical startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Vincent Lepreux last invest?

The most recent investment recorded for Vincent Lepreux closed in Mar 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co